Top-line phase 2 results with Amgen's MariTide drug for obesity are finally in – but the highly anticipated doesn't seem to have lived up to investor expectations. MariTide (maridebart cafraglutide; ...
As the industry looks toward 2026, data center architects and system designers face a convergence of pressures that make storage design more critical than ever. AI workloads continue to drive ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results